Poor
Not Aligned
Patient Risk:
Moderate
Summary
None of the supplied claims about muscle pain incidence, severity, location, exercise exacerbation, or study percentages are supported by the provided FDA label excerpts; the only potentially label-consistent elements are general statements that LIPITOR can cause myalgia and that risk exists, but even those are not supported with the specific quantitative details given.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Label excerpt 12.1 describes LIPITOR as an HMG-CoA reductase inhibitor (statin class).
Unsupported Statements
Lipitor (atorvastatin) is a statin medication that works by reducing the production of LDL (low-density lipoprotein) cholesterol in the liver.
No provided label excerpt states that atorvastatin reduces the production of LDL specifically in the liver using that wording. The label excerpt 12.1 states it lowers plasma cholesterol/lipoprotein levels and is an HMG-CoA reductase inhibitor, but it does not support the specific 'reducing the production of LDL cholesterol in the liver' phrasing.
Muscle pain (myalgia) is a side effect of Lipitor.
Label excerpt 6.1 includes myalgia as a clinical trial adverse experience (0.7%), supporting myalgia as an adverse reaction; however the claim is not supported in the prompt as 'side effect' broadly—still, myalgia is present in label excerpts, so this is only partially unsupported. (For conservatism against the given label excerpts, the more specific quantitative claims are unsupported; overall this item is counted as unsupported only if required to exactly match 'muscle pain (myalgia) is a side effect'.)
Up to 10% of people taking Lipitor experience muscle pain.
The provided label excerpt 6.1 reports myalgia at 0.7% (and separately other adverse reactions), and does not state 'up to 10%'.
The pain from Lipitor can range from mild to severe.
No provided label excerpt describes severity grading of myalgia.
The muscle pain caused by Lipitor can occur in any muscle group.
No provided label excerpt describes muscle-group distribution.
The muscle pain caused by Lipitor is most commonly felt in the arms, legs, and back.
No provided label excerpt specifies arm/leg/back predominance for myalgia.
Exercise can exacerbate muscle pain caused by Lipitor.
No provided label excerpt mentions exercise affecting muscle pain/myopathy.
Studies have shown that people who take Lipitor and exercise regularly are more likely to experience muscle pain than those who take the medication alone.
No provided label excerpt includes any study comparing muscle pain incidence by exercise exposure.
In a study, 15% of patients who took Lipitor and exercised regularly experienced muscle pain.
No provided label excerpt includes this study or the 15% figure for myalgia.
In the same study, 5% of patients who took Lipitor alone experienced muscle pain.
No provided label excerpt includes this study or the 5% figure for myalgia.
Contradictions
Important Omissions
Quantitative label incidence for myalgia from the provided label excerpt (myalgia 0.7%) if the intent was to provide frequency of muscle pain.
Importance:
Moderate
Relevant label safety context for skeletal muscle events (e.g., myopathy/rhabdomyolysis and guidance to temporarily withhold/discontinue with acute serious conditions suggestive of myopathy) rather than only general muscle-pain claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce specific magnitude and study-based probabilities (e.g., up to 10%, 15% vs 5%) and exercise-related exacerbation that are not supported by the provided label excerpts; unsupported overestimation of incidence could influence risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple muscle pain/myalgia claims (frequency, severity, distribution, and exercise interaction with quantitative comparisons) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label sections (e.g., label listing of myalgia as an adverse reaction with the provided incidence 0.7%, and skeletal muscle warning language about myopathy/rhabdomyolysis risk and withholding/discontinuation guidance). Remove or rephrase unsupported quantitative and exercise-related statements.